Page last updated: 2024-12-08
loflazepic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
loflazepic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 155667 |
SCHEMBL ID | 2696462 |
MeSH ID | M0120793 |
Synonyms (17)
Synonym |
---|
7-chloro-5-(2-fluorophenyl)-2-oxo-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid |
loflazepic acid |
unii-y3r871duq5 |
y3r871duq5 , |
71735-10-9 |
7-chloro-5-(2-fluorophenyl) 2,3-dihydro-2-oxo-1h-1,4-benzodiazepine-3-carboxylic acid |
cm-6913 |
1h-1,4-benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo- |
loflazepate |
(+/-)-loflazepic acid |
7-chloro-5-(2-fluorophenyl)-3-carboxy-2,3-dihydro-1h-1,4-benzodiazepine-2-one |
SCHEMBL2696462 |
7-chloro-5-(2-fluorophenyl)-2-hydroxy-3h-1,4-benzodiazepine-3-carboxylic acid |
DTXSID00992350 |
7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1h-benzo[e][1,4]diazepine-3-carboxylic acid |
Q27294228 |
AKOS040752651 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (20.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |